Welcome to our dedicated page for Harte Hanks SEC filings (Ticker: HHS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Searching for the numbers behind Harte Hanks’ data-driven marketing engine? Investors typically open the company’s filings to see how cyclical client budgets affect revenue, whether Customer Care margins are expanding, and how logistics costs move the bottom line. Yet a single Harte Hanks annual report 10-K can exceed 250 pages—hardly light reading.
Stock Titan distills every Harte Hanks SEC filing into plain language. Our AI-powered summaries flag segment performance in the 10-K, spotlight cash-flow shifts in the Harte Hanks quarterly earnings report 10-Q filing, and translate 8-K material events explained in minutes. Need to monitor Harte Hanks insider trading Form 4 transactions? Receive real-time alerts the moment a director buys or sells. Curious about the proxy statement executive compensation tables? We highlight pay structures and incentive metrics without the jargon.
Use cases go further: track Harte Hanks executive stock transactions Form 4 to gauge management sentiment; compare marketing-services growth quarter over quarter with our earnings report filing analysis; or get notified when a new contract announcement hits EDGAR so you can act before the market does. Whether you’re understanding Harte Hanks SEC documents with AI or simply want Harte Hanks SEC filings explained simply, Stock Titan delivers every document—10-K, 10-Q, 8-K, Form 4—complete with expert context and historical trends, all updated in real time.
UBS AG is offering $170,000 in Trigger Autocallable Contingent Yield Notes linked to the common stock of UnitedHealth Group Incorporated (UNH). The three-year notes pay a 10.12% p.a. contingent coupon each quarter only when UNH’s closing price is at or above the Coupon Barrier of $185.13 (60% of the $308.55 Initial Level). If UNH closes at or above the Initial Level on any observation date prior to maturity, the notes are automatically called and investors receive the $10 principal plus the applicable coupon.
If not called, principal is protected at maturity only when the Final Level is at or above the Downside Threshold (also $185.13). Should UNH finish below this threshold, repayment equals $10 × (1 + underlying return), exposing investors to a one-for-one loss that could reach 100% of capital.
- Issue price: $10 per note (minimum purchase 100 notes).
- Estimated initial value: $9.51, reflecting underwriting discount ($0.225 per note) and hedging/issuance costs.
- Observation schedule: Quarterly dates from 6 Oct 2025 through 6 Jul 2028; maturity 10 Jul 2028.
- Credit risk: Unsubordinated, unsecured obligations of UBS AG; payments depend on UBS solvency and are not FDIC-insured.
- Liquidity: Notes will not be listed; secondary market making is at UBS’s discretion and may involve significant bid–ask spreads.
Key risk highlights include potential loss of up to 100% of principal, non-payment of coupons if UNH trades below the barrier, valuation and liquidity uncertainties, conflicts of interest in pricing and hedging, and complex U.S. tax treatment. The product may appeal to investors comfortable with single-stock volatility who seek enhanced income and can tolerate both equity downside and issuer credit exposure.
Harte Hanks (HHS) has filed a Form 4 revealing that General Counsel Robert T. Wyman received 25,000 restricted stock units (RSUs) on 2 June 2025 at a reference price of $4.55 per share. The RSUs vest in three equal annual tranches on each anniversary of the grant date, encouraging long-term retention and alignment with shareholder interests.
After the award, Wyman reports 27,217 directly held common shares and 33,334 unvested RSUs—25,000 from the new 2025 grant plus 8,334 remaining from a 12,500-share grant made on 4 Mar 2024. The RSUs are held indirectly by the company until they vest, and no derivative securities, option exercises or open-market transactions were disclosed.
The filing represents routine executive equity compensation rather than an outright purchase. Immediate cash outlay is zero, and the incremental dilution from 25,000 shares is expected to be negligible relative to the company’s total share count. While the grant reinforces incentive alignment, it is unlikely to have a material impact on Harte Hanks’ near-term valuation or trading dynamics.
Form 4 overview: On 06/30/2025, UFP Industries (UFPI) Chief Financial Officer Michael R. Cole reported the acquisition of 14 phantom stock units at an implied price of $99.36 apiece through the company’s Deferred Compensation Plan. Each unit converts into one share of UFPI common stock upon the executive’s death, disability, or retirement.
After this transaction, Cole’s total beneficial ownership rises to 31,617 share-equivalents, all held directly. No open-market purchases or sales of common shares were disclosed, and there was no change in derivative positions other than the incremental award.
Given the transaction’s small dollar value (≈ $1.4 thousand) and its deferred settlement terms, the filing is regarded as routine and non-material for near-term valuation. Nonetheless, ongoing insider accumulation can be interpreted as continued management alignment with shareholder interests over the long run.
FAQ
What is the current stock price of Harte Hanks (HHS)?
What is the market cap of Harte Hanks (HHS)?
What are the main business segments of Harte Hanks?
How does Harte Hanks utilize data and technology in its services?
What industries does Harte Hanks serve?
How does Harte Hanks differentiate itself from competitors?
Does Harte Hanks have a global presence?
What type of companies can benefit from Harte Hanks' services?
How does Harte Hanks support customer retention and engagement?
What is the core value proposition of Harte Hanks?
